Summary | |
---|---|
Symbol | MCF2 |
Name | MCF.2 cell line derived transforming sequence |
Aliases | DBL; ARHGEF21; Oncogene MCF2 (oncogene DBL); proto-oncogene MCF-2; Proto-oncogene DBL |
Chromosomal Location | Xq26.3-q27.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cytoplasm ; SUBCELLULAR LOCATION: Isoform 1: Membrane.; SUBCELLULAR LOCATION: Isoform 3: Membrane. Note=Colocalizes with CDC42 to plasma membrane. |
Domain |
PF13716 Divergent CRAL/TRIO domain PF00169 PH domain PF00621 RhoGEF domain |
Function |
Guanine nucleotide exchange factor (GEF) that modulates the Rho family of GTPases. Promotes the conversion of some member of the Rho family GTPase from the GDP-bound to the GTP-bound form. Isoform 1 exhibits no activity toward RHOA, RAC1 or CDC42. Isoform 2 exhibits decreased GEF activity toward CDC42. Isoform 3 exhibits a weak but significant activity toward RAC1 and CDC42. Isoform 4 exhibits significant activity toward RHOA and CDC42. The truncated DBL oncogene is active toward RHOA, RAC1 and CDC42. |
Biological Process |
GO:0007265 Ras protein signal transduction GO:0007266 Rho protein signal transduction GO:0016358 dendrite development GO:0035023 regulation of Rho protein signal transduction GO:0046578 regulation of Ras protein signal transduction GO:0051056 regulation of small GTPase mediated signal transduction |
Molecular Function |
GO:0005085 guanyl-nucleotide exchange factor activity GO:0005088 Ras guanyl-nucleotide exchange factor activity GO:0005089 Rho guanyl-nucleotide exchange factor activity |
Cellular Component | - |
KEGG | - |
Reactome |
R-HSA-204998: Cell death signalling via NRAGE, NRIF and NADE R-HSA-416482: G alpha (12/13) signalling events R-HSA-388396: GPCR downstream signaling R-HSA-193648: NRAGE signals death through JNK R-HSA-194840: Rho GTPase cycle R-HSA-162582: Signal Transduction R-HSA-372790: Signaling by GPCR R-HSA-194315: Signaling by Rho GTPases R-HSA-166520: Signalling by NGF R-HSA-193704: p75 NTR receptor-mediated signalling |
Summary | |
---|---|
Symbol | MCF2 |
Name | MCF.2 cell line derived transforming sequence |
Aliases | DBL; ARHGEF21; Oncogene MCF2 (oncogene DBL); proto-oncogene MCF-2; Proto-oncogene DBL |
Chromosomal Location | Xq26.3-q27.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between MCF2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
There is no record. |
Summary | |
---|---|
Symbol | MCF2 |
Name | MCF.2 cell line derived transforming sequence |
Aliases | DBL; ARHGEF21; Oncogene MCF2 (oncogene DBL); proto-oncogene MCF-2; Proto-oncogene DBL |
Chromosomal Location | Xq26.3-q27.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of MCF2 in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | MCF2 |
Name | MCF.2 cell line derived transforming sequence |
Aliases | DBL; ARHGEF21; Oncogene MCF2 (oncogene DBL); proto-oncogene MCF-2; Proto-oncogene DBL |
Chromosomal Location | Xq26.3-q27.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of MCF2 in various data sets.
|
Points in the above scatter plot represent the mutation difference of MCF2 in various data sets.
|
Summary | |
---|---|
Symbol | MCF2 |
Name | MCF.2 cell line derived transforming sequence |
Aliases | DBL; ARHGEF21; Oncogene MCF2 (oncogene DBL); proto-oncogene MCF-2; Proto-oncogene DBL |
Chromosomal Location | Xq26.3-q27.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MCF2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | MCF2 |
Name | MCF.2 cell line derived transforming sequence |
Aliases | DBL; ARHGEF21; Oncogene MCF2 (oncogene DBL); proto-oncogene MCF-2; Proto-oncogene DBL |
Chromosomal Location | Xq26.3-q27.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MCF2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MCF2. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | MCF2 |
Name | MCF.2 cell line derived transforming sequence |
Aliases | DBL; ARHGEF21; Oncogene MCF2 (oncogene DBL); proto-oncogene MCF-2; Proto-oncogene DBL |
Chromosomal Location | Xq26.3-q27.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MCF2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | MCF2 |
Name | MCF.2 cell line derived transforming sequence |
Aliases | DBL; ARHGEF21; Oncogene MCF2 (oncogene DBL); proto-oncogene MCF-2; Proto-oncogene DBL |
Chromosomal Location | Xq26.3-q27.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of MCF2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | MCF2 |
Name | MCF.2 cell line derived transforming sequence |
Aliases | DBL; ARHGEF21; Oncogene MCF2 (oncogene DBL); proto-oncogene MCF-2; Proto-oncogene DBL |
Chromosomal Location | Xq26.3-q27.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between MCF2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | MCF2 |
Name | MCF.2 cell line derived transforming sequence |
Aliases | DBL; ARHGEF21; Oncogene MCF2 (oncogene DBL); proto-oncogene MCF-2; Proto-oncogene DBL |
Chromosomal Location | Xq26.3-q27.1 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting MCF2 collected from DrugBank database. |
There is no record. |